BMO Capital Initiates Coverage On Ionis Pharmaceuticals with Market Perform Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Positive 58.7%

Neg 0% Neu 0% Pos 58.7%

BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform rating and announces Price Target of $60.